Abstract
BackgroundRenal cell carcinoma (RCC) represents only 2-3% of all cancers. Sunitinib is a standard initial therapy in advanced and metastatic renal cell carcinoma.PurposeA retrospective review was performed to assess the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have